Fenofibrate

also known as Tricor · Antara · FENO · Lipanthyl · Lipidil Supra · FEN · fenofibrate (Tricor) · Lipilfen · +4 more

Small molecule targets PPARA via activation

Developed for: hyperlipidemia · primary biliary cholangitis · type 2 diabetes mellitus · hypertriglyceridemia · hyperlipidemia, combined, 2 · cardiovascular disorder · diabetic retinopathy · HIV infectious disease
+50 more
· diabetes mellitus · diabetic kidney disease · NAFLD1 · obesity disorder · coronary artery disorder · fatty liver disease · hyperbilirubinemia · hyperlipoproteinemia · metabolic dysfunction-associated steatohepatitis · metabolic syndrome X · prediabetes syndrome · primary sclerosing cholangitis · type 1 diabetes mellitus · acute coronary syndrome · aortic valve stenosis · central nervous system cancer · cervical cancer · cervical intraepithelial neoplasia · childhood malignant neoplasm · cholestasis · congenital nonhemolytic jaundice · COVID-19 · glucose metabolism disease · hyperlipoproteinemia type 3 · hypertensive disorder · hypertriglyceridemia 2 · hypoalphalipoproteinemia · inborn errors of metabolism · infectious disease with sepsis · Klinefelter syndrome · leukemia · lipodystrophy · lymphoma · macular telangiectasia type 2 · metabolic disease · neuroblastoma · plasma cell myeloma · polycystic ovary syndrome · proteinuria · radiodermatitis · sarcoma · sleep apnea syndrome · spinal cord injury · alcohol dependence · female breast carcinoma · Huntington disease · inflammatory bowel disease · lip disorder · peripheral neuropathy · sexual disorder
Investigated by: Solvay Pharmaceuticals · Xijing Hospital of Digestive Diseases · Abbott · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Chong Kun Dang Pharmaceutical
+105 more
· GlaxoSmithKline · Hanlim Pharm. Co., Ltd. · National Eye Institute (NEI) · National Institute of Allergy and Infectious Diseases (NIAID) · National Institutes of Health (NIH) · Pfizer · VA Office of Research and Development · Gachon University Gil Medical Center · Gilead Sciences · Han Ying · Mayo Clinic · Merck Sharp & Dohme LLC · National Institute on Aging (NIA) · National Taiwan University Hospital · Organon and Co · Shionogi · University of Florida · University of Miami · University of Michigan · University of Oxford · Veloxis Pharmaceuticals · Washington University School of Medicine · Yonsei University · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Aegerion Pharmaceuticals, Inc. · Ahmad Slim · Ain Shams University · Alessandro Doria · AstraZeneca · Azienda Ospedaliera di Padova · Barzilai Medical Center · Baylor College of Medicine · Beijing 302 Hospital · Beijing Chao Yang Hospital · Boston Children's Hospital · British Heart Foundation · Centers for Disease Control and Prevention · Children's Memorial Health Institute, Poland · Daewon Pharmaceutical Co., Ltd. · Daewoong Pharmaceutical Co. LTD. · Dana-Farber Cancer Institute · Dnipropetrovsk State Medical Academy · Hoda A. Atta · IlDong Pharmaceutical Co Ltd · Indonesia University · Institut Investigacio Sanitaria Pere Virgili · Integrium · Intermountain Health Care, Inc. · Jaeb Center for Health Research · Juvenile Diabetes Research Foundation · Juvenile Diabetes Research Foundation Australia · Kaiser Permanente · Korea University Anam Hospital · Laboratorios Silanes S.A. de C.V. · Leducq Foundation · Legacy Community Health Center · Lindsay Ferguson, MD · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Mario Luca Morieri · McGill University Health Centre/Research Institute of the McGill University Health Centre · Medical University of Silesia · Medical University of South Carolina · Medical University of Warsaw · Ministry of Scientific Research and Information Technology, Poland · Muhammad Zark · Mylan Pharmaceuticals Inc · NHS Scotland Diabetic Retinopathy Screening Collaborative · National Cancer Institute (NCI) · National Health and Medical Research Council, Australia · National Institute for Health Research, United Kingdom · National Institutes of Health Clinical Center (CC) · National Medical Research Council (NMRC), Singapore · Nazareth Hospital · Novartis · all 111 on the full record

Regulatory milestones approvals, filings & regulatory actions · 4 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Pravafenix	—	2011-04-14	europa.eu ↗
Label expansion	US (FDA)	ANTARA (MICRONIZED)	—	2005-10-21	fda.gov ↗
Label expansion	US (FDA)	TRICOR (MICRONIZED)	—	2000-04-24	fda.gov ↗
Approved	US (FDA)	TRICOR (MICRONIZED)	—	1993-12-31	fda.gov ↗

Trials 122 · started per year

today

US approved 1993

EU approved 2011

199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT07104201	Mar 2025 → Mar 2035 expected	primary biliary cholangitis	Xijing Hospital of Digestive Diseases	Recruiting	No outcome recorded
Phase 0	NCT06591455	Sep 2024 → Aug 2025	primary biliary cholangitis	Han Ying	Completed	No outcome recorded
Phase 112 trials
Phase 1	NCT06191133	Nov 2024 → Jun 2026 overdue	cervical cancer, cervical intraepithelial neoplasia	Lindsay Ferguson, MD	Recruiting	No outcome recorded
Phase 1	NCT03346187	May 2017	hyperlipidemia	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT02891408	Sep 2016 → May 2019	metabolic dysfunction-associated steatohepatitis	Gilead Sciences	Completed	No outcome recorded
Phase 1	NCT02250976	Sep → Oct 2014	—	Hanlim Pharm. Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT02066207	Mar → Apr 2014	familial hypercholesterolemia, hyperlipidemia, combined, 2	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 1	NCT01767610	Jan → Mar 2013	—	Hanlim Pharm. Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT01723735	Nov 2012 → Jul 2013	hyperlipoproteinemia	Sanofi	Completed	No outcome recorded
Phase 1	NCT01353404	Jun → Aug 2011	hyperlipidemia	Samyang Biopharmaceuticals Corporation	Completed	No outcome recorded
Phase 1	NCT01148004	May 2010 → Jul 2013	HIV infectious disease, hypertriglyceridemia 2	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded
Phase 1	NCT01109758	Mar → Jul 2008	—	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00376285	Nov 2006 → ?	obesity disorder	Pfizer	Withdrawn	No outcome recorded
Phase 1	NCT00543647	Aug 2002 → Mar 2003	—	Solvay Pharmaceuticals	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT02965911	Jan 2016 → Sep 2021	primary biliary cholangitis	Beijing 302 Hospital	Withdrawn	No outcome recorded
Phase 1/2	NCT01142323	Oct 2010 → Dec 2012	primary sclerosing cholangitis	University of Miami	Terminated	No outcome recorded
Phase 221 trials
Phase 2	NCT07572552	May 2026 → Apr 2027 expected	infectious disease with sepsis	Tanta University	Not yet recruiting	No outcome recorded
Phase 2	NCT06905054	Apr 2025 → Mar 2028 expected	primary sclerosing cholangitis	Mayo Clinic	Recruiting	No outcome recorded
Phase 2	NCT05909800	Sep 2022 → Jul 2024	type 1 diabetes mellitus	Medical University of Warsaw	Unknown	No outcome recorded
Phase 2	NCT05514119	Aug 2022 → Jun 2024	—	Mayo Clinic	Terminated	No outcome recorded
Phase 2	NCT04907084	Apr 2022 → Mar 2024 overdue	macular telangiectasia type 2	The Lowy Medical Research Institute Limited	Active not recruiting	No outcome recorded
Phase 2	NCT04929379	Jan 2022 → May 2025 overdue	diabetic kidney disease	Alessandro Doria	Active not recruiting	No outcome recorded
Phase 2	NCT06623539	Dec 2020 → Jun 2025 overdue	NAFLD1	Yokohama City University	Active not recruiting	No outcome recorded
Phase 2	NCT03586674	Nov 2017 → Jun 2018	cholestasis	Hoda A. Atta	Completed	No outcome recorded
Phase 2	NCT02781584	Jun 2016 → Dec 2020	NAFLD1, metabolic dysfunction-associated steatohepatitis	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT01965834	Nov 2012 → Mar 2016	plasma cell myeloma	University of Miami	Terminated	No outcome recorded
Phase 2	NCT01426438	Nov 2011 → Oct 2013	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	No outcome recorded
Phase 2	NCT00575042	Aug 2007 → Aug 2009	primary biliary cholangitis	University of Florida	Completed	No outcome recorded
Phase 2	NCT00504829	Jul 2007 → Feb 2008	hyperlipidemia	Veloxis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00359281	Mar 2006 → Nov 2007	—	Aegerion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT00816829	Sep 2005 → Jan 2008	hyperlipidemia, obesity disorder, sleep apnea syndrome	Solvay Pharmaceuticals	Terminated	No outcome recorded
Phase 2	NCT00357500	Jan 2005 → Feb 2013	central nervous system cancer, childhood malignant neoplasm, leukemia, lymphoma +2	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 2	NCT00349635	Oct 2004 → ?	obesity disorder	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00703482	May 2003 → Sep 2004	—	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00361751	May 2003 → May 2005	—	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 2	NCT00703755	Mar 2003 → Jun 2004	metabolic syndrome X	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00076518	? → Sep 2005	HIV infectious disease, hypertriglyceridemia	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 2/38 trials
Phase 2/3	NCT06346743	Apr → Jul 2024	hyperbilirubinemia	Muhammad Zark	Unknown	No outcome recorded
Phase 2/3	NCT06174402	Aug 2023 → Jul 2026 overdue	primary biliary cholangitis	Han Ying	Active not recruiting	No outcome recorded
Phase 2/3	NCT05749822	Feb 2023 → Dec 2027 expected	primary biliary cholangitis	Xijing Hospital of Digestive Diseases	Recruiting	No outcome recorded
Phase 2/3	NCT06365424	Apr 2017 → Apr 2027 expected	primary biliary cholangitis	Xijing Hospital of Digestive Diseases	Recruiting	No outcome recorded
Phase 2/3	NCT02455336	May 2015 → Aug 2018	hyperlipidemia, spinal cord injury	VA Office of Research and Development	Completed	No outcome recorded
Phase 2/3	NCT00664859	Oct 2007 → Feb 2009	hyperlipidemia	Veloxis Pharmaceuticals	Completed	No outcome recorded
Phase 2/3	NCT00362765	Oct 2006 → Jul 2007	hyperlipidemia, type 2 diabetes mellitus	Solvay Pharmaceuticals	Terminated	No outcome recorded
Phase 2/3	NCT00349128	Jan 2004 → ?	hyperlipidemia	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 335 trials
Phase 3	NCT07296458	Dec 2025 → Dec 2028 expected	primary biliary cholangitis	Xijing Hospital of Digestive Diseases	Recruiting	No outcome recorded
Phase 3	NCT06755541	Jan 2024 → Dec 2035 expected	primary biliary cholangitis	Xijing Hospital of Digestive Diseases	Recruiting	No outcome recorded
Phase 3	NCT06755151	Jan 2024 → Dec 2035 expected	primary biliary cholangitis	Xijing Hospital of Digestive Diseases	Recruiting	No outcome recorded
Phase 3	NCT05751967	Feb 2023 → Dec 2027 expected	primary biliary cholangitis	Xijing Hospital of Digestive Diseases	Recruiting	No outcome recorded
Phase 3	NCT04882293	Feb → May 2022	type 2 diabetes mellitus	Laboratorios Silanes S.A. de C.V.	Unknown	No outcome recorded
Phase 3	NCT04661358	Mar 2021 → Dec 2029 expected	diabetic retinopathy	Jaeb Center for Health Research	Active not recruiting	No outcome recorded
Phase 3	NCT04661930	Jan 2021 → May 2022	COVID-19	Yaakov Nahmias	Unknown	No outcome recorded
Phase 3	NCT03869931	Mar 2019 → Apr 2021	diabetes mellitus, diabetic kidney disease	Singapore General Hospital	Unknown	No outcome recorded
Phase 3	NCT01320345	Nov 2016 → Aug 2026 overdue	diabetic kidney disease, diabetic retinopathy, type 1 diabetes mellitus	University of Sydney	Active not recruiting	No outcome recorded
Phase 3	NCT02823353	Apr 2016 → May 2022	primary biliary cholangitis	Xijing Hospital of Digestive Diseases	Completed	No outcome recorded
Phase 3	NCT02823366	Jan 2016 → Dec 2023	primary biliary cholangitis	Xijing Hospital of Digestive Diseases	Unknown	No outcome recorded
Phase 3	NCT03618797	Nov 2015 → Jan 2018	hyperlipidemia, combined, 2	Hanlim Pharm. Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02262143	Nov 2014 → Oct 2016	hyperlipidemia, combined, 2	IlDong Pharmaceutical Co Ltd	Completed	No outcome recorded
Phase 3	NCT02166593	May 2014 → Jan 2018	hyperlipidemia, combined, 2	Yooyoung Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT01956201	Dec 2013 → Aug 2016	hyperlipidemia, combined, 2	Chong Kun Dang Pharmaceutical	Unknown	No outcome recorded
Phase 3	NCT01674712	Jun 2012 → Oct 2013	hyperlipidemia	Abbott	Completed	No outcome recorded
Phase 3	NCT00459745	Apr 2007 → Apr 2008	hyperlipidemia, combined, 2	Shionogi	Completed	No outcome recorded
Phase 3	NCT00490178	Mar 2007 → ?	hyperlipidemia, type 2 diabetes mellitus	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00362323	Oct 2006 → Aug 2008	hyperlipidemia	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00362934	Oct 2006 → Aug 2008	hyperlipidemia	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00362206	Sep 2006 → Sep 2008	hyperlipidemia	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00361868	Jun 2006 → Dec 2007	glucose metabolism disease, hyperlipidemia	Solvay Pharmaceuticals	Terminated	No outcome recorded
Phase 3	NCT00352183	Jan 2006 → Aug 2008	cardiovascular disorder	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00349375	Nov 2005 → Sep 2008	hyperlipidemia	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00348725	Apr 2005 → ?	hyperlipidemia	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00261352	Mar 2005 → Dec 2006	type 2 diabetes mellitus	AstraZeneca	Terminated	No outcome recorded
Phase 3	NCT00139061	Mar 2005 → May 2006	hyperlipidemia	Pfizer	Completed	No outcome recorded
Phase 3	NCT00145431	Mar 2005 → Dec 2006	hyperlipoproteinemia type 3	Pfizer	Terminated	No outcome recorded
Phase 3	NCT00349284	Jan 2005 → ?	hyperlipidemia, combined, 2	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00195793	Aug 2004 → ?	hyperlipidemia	Abbott	Completed	No outcome recorded
Phase 3	NCT00542178	Oct 2003 → Dec 2009	diabetic retinopathy	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 3	NCT00092573	Apr 2003 → Nov 2004	hyperlipidemia, hypertriglyceridemia	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00092560	Dec 2002 → Dec 2003	hyperlipidemia, hypertriglyceridemia	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00000620	Sep 1999 → Jun 2009	atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 3	NCT00006412	? → May 2003	HIV infectious disease, lipodystrophy	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 419 trials
Phase 4	NCT06451900	Jul → Nov 2023	congenital nonhemolytic jaundice	Ain Shams University	Completed	No outcome recorded
Phase 4	NCT05498090	Nov 2022 → Jun 2025	Klinefelter syndrome	University of Colorado, Denver	Unknown	No outcome recorded
Phase 4	NCT04528212	Nov 2020 → Nov 2021	type 2 diabetes mellitus	Rehab Werida	Completed	No outcome recorded
Phase 4	NCT03829514	Feb 2019 → Mar 2020	type 2 diabetes mellitus	Medical University of South Carolina	Completed	No outcome recorded
Phase 4	NCT03874260	Jul 2018 → Jan 2020	hyperlipidemia	Daewon Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 4	NCT03439345	Jul 2018 → Nov 2023	diabetic retinopathy	University of Oxford	Completed	No outcome recorded
Phase 4	NCT02314533	Dec 2014 → Dec 2016	proteinuria	Beijing Chao Yang Hospital	Unknown	No outcome recorded
Phase 4	NCT02232360	Jan 2014 → Dec 2020	coronary artery disorder	Gachon University Gil Medical Center	Unknown	No outcome recorded
Phase 4	NCT02015988	Jan 2014 → Sep 2016	acute coronary syndrome, hypertriglyceridemia, type 2 diabetes mellitus	Dnipropetrovsk State Medical Academy	Unknown	No outcome recorded
Phase 4	NCT01927315	Aug 2013 → Oct 2019	diabetes mellitus, diabetic retinopathy	University of Padova	Completed	No outcome recorded
Phase 4	NCT01462877	Oct 2011 → Feb 2014	cardiovascular disorder, hyperlipidemia, hypertriglyceridemia	Abbott	Completed	No outcome recorded
Phase 4	NCT00843661	Mar 2009 → Dec 2011	HIV infectious disease, hyperlipidemia	Ospedale di Circolo - Fondazione Macchi	Unknown	No outcome recorded
Phase 4	NCT01414803	Mar 2009 → Apr 2011	hyperlipidemia	Yonsei University	Completed	No outcome recorded
Phase 4	NCT02153879	Feb 2009 → Dec 2011	hyperlipidemia, type 2 diabetes mellitus	Institut Investigacio Sanitaria Pere Virgili	Completed	No outcome recorded
Phase 4	NCT01122355	Feb 2009 → Jan 2010	metabolic disease	Yonsei University	Completed	No outcome recorded
Phase 4	NCT00819910	Sep 2008 → May 2010	hypertriglyceridemia	Ahmad Slim	Terminated	No outcome recorded
Phase 4	NCT00385658	Aug 2006 → Mar 2007	hyperlipidemia	Novartis	Completed	No outcome recorded
Phase 4	NCT00891293	Mar 2006 → May 2008	hypertriglyceridemia	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00745407	Jan 2005 → Aug 2008	hypertriglyceridemia	Gachon University Gil Medical Center	Completed	No outcome recorded

Phase not applicable21 trials
—	NCT06293417	Mar 2024 → Feb 2027 expected	hyperlipidemia, type 2 diabetes mellitus	Korea University Anam Hospital	Recruiting	No outcome recorded
—	NCT05542147	Jul 2022 → Nov 2024	cardiovascular disorder, type 2 diabetes mellitus	Mario Luca Morieri	Completed	No outcome recorded
—	NCT04868019	Sep 2021 → Feb 2022	hyperbilirubinemia	Shaheed Zulfiqar Ali Bhutto Medical University	Unknown	No outcome recorded
—	NCT05256758	May 2019 → Mar 2022	aortic valve stenosis	University of Oxford	Unknown	No outcome recorded
—	NCT03557983	Jun 2018 → Apr 2020	radiodermatitis	Second Affiliated Hospital of Soochow University	Unknown	No outcome recorded
—	NCT04885153	Nov 2016 → Jul 2017	diabetes mellitus, diabetic retinopathy, hyperlipidemia	Indonesia University	Completed	No outcome recorded
—	NCT01752842	Mar 2013 → Feb 2018	type 2 diabetes mellitus	Washington University School of Medicine	Completed	No outcome recorded
—	NCT01280604	Oct 2010 → Jan 2013	hyperlipidemia	Kaiser Permanente	Completed	No outcome recorded
—	NCT01048502	Jan 2010 → May 2011	cardiovascular disorder	University of Pennsylvania	Completed	No outcome recorded
—	NCT00884819	Dec 2008 → Feb 2015	polycystic ovary syndrome	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Terminated	No outcome recorded
—	NCT01099176	May 2008 → May 2009	hyperlipidemia, prediabetes syndrome	Medical University of Silesia	Completed	No outcome recorded
—	NCT00470262	Jan 2007 → Dec 2012	metabolic syndrome X, prediabetes syndrome	VA Office of Research and Development	Completed	No outcome recorded
—	NCT00458055	Nov 2006 → Sep 2007	coronary atherosclerosis, hypoalphalipoproteinemia, inborn errors of metabolism	McGill University Health Centre/Research Institute of the McGill University Health Centre	Completed	No outcome recorded
—	NCT01289639	Oct 2005 → Aug 2013	fatty liver disease	VA Office of Research and Development	Terminated	No outcome recorded
—	NCT00252499	Oct 2005 → Aug 2010	fatty liver disease	US Department of Veterans Affairs	Terminated	No outcome recorded
—	NCT00627653	Oct 2005 → Dec 2009	cardiovascular disorder	National Institute on Aging (NIA)	Unknown	No outcome recorded
—	NCT00262964	Oct 2004 → Dec 2008	NAFLD1	Washington University School of Medicine	Completed	No outcome recorded
—	NCT00246376	Jan 2004 → Sep 2009	HIV infectious disease, atherosclerosis, heart disorder, hyperlipidemia +1	Baylor College of Medicine	Completed	No outcome recorded
—	NCT00309712	Aug 2002 → Sep 2006	hyperlipidemia, combined, 2, type 2 diabetes mellitus	Intermountain Health Care, Inc.	Completed	No outcome recorded
—	NCT00422396	Jan 2001 → Apr 2002	hypertriglyceridemia	University of Michigan	Completed	No outcome recorded
—	NCT00483210	—	—	University of Arkansas	Withdrawn	No outcome recorded

Phase not stated2 trials
—	NCT00965315	—	cardiovascular disorder	National Taiwan University Hospital	Available	No outcome recorded
—	NCT00934258	—	hyperlipidemia	National Taiwan University Hospital	Available	No outcome recorded

Also used as a comparator or background therapy in 53 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT06796660 Background	Sep 2025 → Dec 2027 expected	chronic kidney disease	Liu Zhanghong	Not yet recruiting	No outcome recorded
Phase 214 trials
Phase 2	NCT06155331 Comparator	Dec 2023 → Jan 2025	female breast carcinoma	Tanta University	Completed	No outcome recorded
Phase 2	NCT05781698 Comparator	Mar 2023 → Oct 2024	inflammatory bowel disease	Tanta University	Completed	No outcome recorded
Phase 2	NCT03515213 Comparator	Apr 2017 → Aug 2021	Huntington disease	University of California, Irvine	Completed	No outcome recorded
Phase 2	NCT02890992 Background	Sep 2016 → Sep 2018	familial hypercholesterolemia	Sanofi	Completed	No outcome recorded
Phase 2	NCT02354976 Comparator	Sep 2015 → May 2016	NAFLD1, hypertriglyceridemia	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT02158273 Comparator	May 2014 → Apr 2016	alcohol dependence	The Scripps Research Institute	Completed	No outcome recorded
Phase 2	NCT01594983 Comparator	Jun 2012 → Jul 2013	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01539616 Comparator	Nov 2011 → Jun 2012	hyperlipidemia, hypertriglyceridemia	Zydus Lifesciences Limited	Completed	No outcome recorded
Phase 2	NCT01141296 Comparator	Apr 2011 → ?	primary biliary cholangitis	University of Miami	Withdrawn	No outcome recorded
Phase 2	NCT00559962 Comparator	Oct 2007 → Oct 2008	hyperlipidemia	Aegerion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT00813527 Comparator	Feb 2006 → Jan 2007	hyperlipidemia	Takeda	Completed	No outcome recorded
Phase 2	NCT00400231 Comparator	Aug 2005 → Dec 2007	metabolic syndrome X	University of Pennsylvania	Completed	No outcome recorded
Phase 2	NCT00169559 Comparator	Nov 2003 → Apr 2005	hyperlipidemia	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00703690 Comparator	Jan 2002 → Dec 2003	metabolic syndrome X	Merck Sharp & Dohme LLC	Terminated	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT05753267 Comparator	Feb 2023 → Sep 2025	inflammatory bowel disease	Tanta University	Completed	No outcome recorded
Phase 2/3	NCT02452255 Comparator	Nov 2015 → Dec 2018	—	The University of Texas Medical Branch, Galveston	Terminated	No outcome recorded
Phase 2/3	NCT00732485 Comparator	Aug 2008 → Dec 2012	—	The University of Texas Medical Branch, Galveston	Withdrawn	No outcome recorded
Phase 39 trials
Phase 3	NCT04998981 Comparator	Sep 2021 → Feb 2023	hyperlipidemia	Kowa Company, Ltd.	Completed	No outcome recorded
Phase 3	NCT03510715 Background	Aug 2018 → Feb 2020	hyperlipidemia	Sanofi	Completed	No outcome recorded
Phase 3	NCT03510884 Background	May 2018 → Jan 2021	hyperlipidemia	Sanofi	Completed	No outcome recorded
Phase 3	NCT03001817 Comparator	Nov 2016 → Jun 2019	—	Kowa Research Institute, Inc.	Completed	No outcome recorded
Phase 3	NCT03011450 Comparator	Nov 2016 → Jul 2019	—	Kowa Research Institute, Inc.	Completed	No outcome recorded
Phase 3	NCT02584504 Background	Nov 2015 → Apr 2017	hyperlipoproteinemia	Sanofi	Completed	No outcome recorded
Phase 3	NCT02023879 Background	Dec 2013 → Oct 2014	hyperlipidemia	Sanofi	Completed	No outcome recorded
Phase 3	NCT01878227 Comparator	Jul 2010 → May 2011	hyperlipoproteinemia	Zhejiang University	Completed	No outcome recorded
Phase 3	NCT00251680 Comparator	Oct 2005 → May 2007	type 2 diabetes mellitus	Takeda	Completed	No outcome recorded

Phase 418 trials
Phase 4	NCT07025005 Comparator	Aug 2025 → Jun 2026 overdue	peripheral neuropathy, plasma cell myeloma	Tanta University	Recruiting	No outcome recorded
Phase 4	NCT04140201 Comparator	Feb → Jun 2020	diabetic retinopathy	Alaa Hassan ElBaz	Unknown	No outcome recorded
Phase 4	NCT02984982 Background	Nov 2016 → Jul 2018	acute coronary syndrome, hyperlipidemia	Sanofi	Completed	No outcome recorded
Phase 4	NCT02642159 Comparator	Mar 2016 → Mar 2017	hyperlipidemia	Sanofi	Completed	No outcome recorded
Phase 4	NCT03615534 Comparator	Oct 2014 → Jun 2015	hypertriglyceridemia 2, obesity disorder	Lewai Sharki Abdulaziz, MSc PhD	Completed	No outcome recorded
Phase 4	NCT02886299 Comparator	Oct 2013 → Jan 2016	—	Cairo University	Completed	No outcome recorded
Phase 4	NCT01574131 Comparator	May 2012 → Feb 2016	—	The University of Texas Medical Branch, Galveston	Terminated	No outcome recorded
Phase 4	NCT01666041 Comparator	Jan 2012 → Feb 2013	hypertriglyceridemia	Gachon University Gil Medical Center	Completed	No outcome recorded
Phase 4	NCT01003847 Comparator	Nov 2009 → Sep 2010	hypertriglyceridemia	Gachon University Gil Medical Center	Completed	No outcome recorded
Phase 4	NCT01010516 Comparator	Oct 2009 → Dec 2011	hyperlipidemia	University of Ioannina	Unknown	No outcome recorded
Phase 4	NCT00872599 Comparator	Sep 2009 → Jan 2012	hypertensive disorder	Vanderbilt University	Completed	No outcome recorded
Phase 4	NCT00923676 Comparator	Apr 2008 → Oct 2015	hyperlipidemia, sexual disorder	University of Campania Luigi Vanvitelli	Unknown	No outcome recorded
Phase 4	NCT00552747 Comparator	Oct 2007 → Mar 2010	coronary artery disorder, hyperlipidemia	National Heart Institute, Mexico	Completed	No outcome recorded
Phase 4	NCT00246636 Background	Oct 2005 → Feb 2007	hypertriglyceridemia	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00809068 Comparator	Aug 2005 → Aug 2009	—	Keogh Institute for Medical Research	Completed	No outcome recorded
Phase 4	NCT00754039 Background	Feb → Sep 2003	familial hyperlipidemia	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT00632840 Comparator	Jun 2001 → Dec 2002	cardiovascular disorder, hypertriglyceridemia, lip disorder, obesity disorder	The University of Western Australia	Completed	No outcome recorded
Phase 4	NCT00304993 Background	Jan 2001 → Feb 2005	metabolic syndrome X	Foundation Research, Florida	Completed	No outcome recorded

Phase not applicable8 trials
—	NCT05813145 Comparator	Jan 2023 → Aug 2024	breast cancer	Damanhour University	Completed	No outcome recorded
—	NCT04418180 Comparator	Jun 2016 → Dec 2018	congenital nonhemolytic jaundice	Mansoura University	Completed	No outcome recorded
—	NCT01974544 Background	May 2013 → Dec 2015	type 2 diabetes mellitus	Pontificia Universidad Catolica de Chile	Unknown	No outcome recorded
—	NCT01101204 Comparator	Jul → Oct 2012	hyperlipidemia, type 2 diabetes mellitus	Medical University of Silesia	Unknown	No outcome recorded
—	NCT00794963 Background	Nov 2008 → May 2010	metabolic syndrome X	Northwell Health	Terminated	No outcome recorded
—	NCT00644592 Comparator	Mar 2008 → Aug 2009	—	University of Florida	Terminated	No outcome recorded
—	NCT00491400 Comparator	Sep 2005 → Dec 2008	diabetes mellitus, metabolic syndrome X	Boston University	Terminated	No outcome recorded
—	NCT00186537 Comparator	Sep 2003 → Sep 2008	hypertriglyceridemia	Stanford University	Completed	No outcome recorded

Press releases naming this drug 5 releases

Date	Issuer	Release
2005-05-16	Teva Branded Pharmaceutical Products R&D, Inc.	Teva's Fenofibrate Product Receives Final Approval; Seeks Three Times Its Lost Profits In Antitrust Lawsuit Against Abbott tevapharm.com ↗
2004-03-08	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Tentative Approval Of Fenofibrate Tablets, 54 Mg, 160 Mg tevapharm.com ↗
2002-09-04	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Approval of Fenofibrate Capsules (micronized), 67mg. will Have 180 Days of Marketing Exclusivity tevapharm.com ↗
2002-04-10	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Approval of Fenofibrate Capsules tevapharm.com ↗
2002-03-21	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Resolution of Patent Litigation for Fenofibrate Capsules tevapharm.com ↗

Evidence & citations 17 cited values

Every value below carries the sentence it was read from. 180 sources stand behind the page.

Field	Value	Cited text
Known as	fenofibrate	“The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia” NCT00664859 ↗ 172 “A Clinical Trial to Evaluate the Pharmacokinetics of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca Under Fed Condition in Healthy Male Volunteers” NCT02250976 ↗ “We evaluated the safety and efficacy of icosapent ethyl (Vascepa) and fenofibrate to mitigate triglyceride elevations in patients with NASH treated with CILO and FIR.” PMID 34999207 ↗ Jan 2022 “40mg atorvastatin combined with 100mg fenofibrate in a tablet for once daily treatment of dyslipidemia and mixed dyslipidemia” NCT00504829 ↗ “Lipid Control: Medications such as atorvastatin calcium tablets (20 mg qd) or fenofibrate capsules (0.2 g qd) can be used.” NCT06796660 ↗ “Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)” NCT01353404 ↗ “Gemfibrozilo or fenofibrate once daily can be used for isolated hypertriglyceridaemia” NCT01974544 ↗ “Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg” NCT03618797 ↗ “Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.” NCT02584504 ↗ “rosuvastatin 10 mg plus fenofibrate 160 mg or rosuvastatin 10 mg.” PMID 22269152 ↗ Jan 2012 “Fenofibrate; 145 mg daily (1/day); oral administration; 10 days” NCT04661930 ↗ “Ezetimibe or Fenofibrate at stable dose as background therapy.” NCT02023879 ↗ “Subjects will receive fenofibrate 54mg daily.” NCT01280604 ↗ “fenofibrate 160 mg po for 16 weeks” NCT01122355 ↗ “267mg of Fenofibrate” NCT01099176 ↗ NCT02886299 ↗ NCT01142323 ↗ NCT03615534 ↗ NCT00304993 ↗ NCT00349284 ↗ NCT00359281 ↗ NCT01003847 ↗ NCT02262143 ↗ NCT04907084 ↗ NCT00732485 ↗ NCT00794963 ↗ NCT07104201 ↗ NCT00965315 ↗ NCT00400231 ↗ NCT01101204 ↗ NCT01539616 ↗ NCT05498090 ↗ NCT00754039 ↗ NCT00543647 ↗ NCT06905054 ↗ NCT00352183 ↗ NCT00361868 ↗ NCT00703690 ↗ NCT00376285 ↗ NCT02166593 ↗ NCT03510715 ↗ NCT06365424 ↗ NCT00349128 ↗ NCT00145431 ↗ NCT00361751 ↗ NCT01280604 ↗ NCT00000620 ↗ NCT02158273 ↗ NCT01878227 ↗ NCT02232360 ↗ NCT01594983 ↗ NCT06191133 ↗ NCT00470262 ↗ NCT06623539 ↗ NCT01141296 ↗ NCT02455336 ↗ NCT03439345 ↗ NCT03557983 ↗ NCT06591455 ↗ NCT00884819 ↗ NCT00422396 ↗ NCT03515213 ↗ NCT03869931 ↗ NCT04140201 ↗ NCT01462877 ↗ NCT04882293 ↗ NCT00923676 ↗ NCT00186537 ↗ NCT06174402 ↗ NCT07025005 ↗ NCT05753267 ↗ NCT03829514 ↗ NCT00348725 ↗ NCT00490178 ↗ NCT00139061 ↗ NCT00559962 ↗ NCT05542147 ↗ NCT00458055 ↗ NCT02314533 ↗ NCT06755541 ↗ NCT00816829 ↗ NCT00542178 ↗ NCT04998981 ↗ NCT01752842 ↗ NCT00891293 ↗ NCT01048502 ↗ NCT00246376 ↗ NCT00575042 ↗ NCT04929379 ↗ NCT05256758 ↗ NCT00169559 ↗ NCT00261352 ↗ NCT02452255 ↗ NCT00627653 ↗ NCT00357500 ↗ NCT05813145 ↗ NCT00459745 ↗ NCT01674712 ↗ NCT02984982 ↗ NCT00362206 ↗ NCT03874260 ↗ NCT01767610 ↗ NCT02354976 ↗ NCT00246636 ↗ NCT04868019 ↗ NCT00745407 ↗ NCT01965834 ↗ NCT06293417 ↗ NCT02965911 ↗ NCT00632840 ↗ NCT06155331 ↗ NCT01574131 ↗ NCT02891408 ↗ NCT00703755 ↗ NCT02823366 ↗ NCT05514119 ↗ NCT05751967 ↗ NCT00362323 ↗ NCT00309712 ↗ NCT00872599 ↗ NCT00006412 ↗ NCT06451900 ↗ NCT02823353 ↗ NCT00349375 ↗ NCT00262964 ↗ NCT00491400 ↗ NCT02890992 ↗ NCT06346743 ↗ NCT05781698 ↗ NCT00644592 ↗ NCT01426438 ↗ NCT00819910 ↗ NCT00092560 ↗ NCT02642159 ↗ NCT00813527 ↗ NCT01289639 ↗ NCT00092573 ↗ NCT03011450 ↗ NCT01010516 ↗ NCT00195793 ↗ NCT02153879 ↗ NCT01109758 ↗ NCT07572552 ↗ NCT02015988 ↗ NCT05749822 ↗ NCT00552747 ↗ NCT00385658 ↗ NCT01927315 ↗ NCT07296458 ↗ NCT01666041 ↗ NCT03001817 ↗ NCT03510884 ↗ NCT01723735 ↗ NCT00076518 ↗ NCT00349635 ↗ NCT00843661 ↗ NCT04885153 ↗ NCT00252499 ↗ NCT06755151 ↗ NCT03346187 ↗ NCT01320345 ↗ NCT00362765 ↗ NCT04528212 ↗ NCT00934258 ↗ NCT00703482 ↗ NCT04418180 ↗ NCT00362934 ↗ NCT00809068 ↗ NCT00483210 ↗ NCT01956201 ↗ NCT02066207 ↗ NCT01148004 ↗ NCT04661358 ↗
Known as	Antara	“Open-label Antara (fenofibrate) + open-label Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]” NCT00891293 ↗ 1 “Antara (fenofibrate) + Lovaza” NCT00246636 ↗
Known as	FEN	“Whole body and liver insulin sensitivity were assessed with a hyperinsulinemic-euglycemic clamp, and insulin signaling and mitochondrial function were measured in muscle...” PMID 17245174 ↗ Feb 2007
Known as	FENO	“receiving placebo (PBO), fenofibrate (FENO), ezetimibe plus FENO (EZE+FENO), or EZE/simvastatin plus FENO (EZE/SIMVA+FENO) for 12 weeks.” PMID 22087637 ↗ Nov 2011 1 “Participants will receive fenofibrate (FENO) 48 mg tablet orally once daily for 2 weeks in the pretreatment phase” NCT02781584 ↗
Known as	fenofibrate (Tricor)	“fenofibrate (Tricor)” NCT00000620 ↗
Known as	Lipanthyl	“Fenofibrate (Lipanthyl®) 200mg capsule will be administered orally with breakfast once daily” NCT02314533 ↗ 1 NCT03586674 ↗
Known as	Lipidil Supra	“Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)” NCT01353404 ↗ 1 “Lipitor(Atorvastatin Calcium Trihydrate 20mg/tablet) + Lipidil supra(Fenofibrate 160mg/tablet)” NCT03346187 ↗
Known as	Lipilfen	“To evaluate the comparative pharmacokinetics and safety of fixed-dose combination versus coadministration of Lipilfen cap.160mg(micronized fenofibrate160mg) and Livalo tab....” NCT02250976 ↗
Known as	NanoCrystal(R)	“OBJECTIVE: To assess the efficacy and safety of coadministration of fenofibrate (NanoCrystal(R)) and ezetimibe in patients with type IIb dyslipidemia and the metabolic syndrome...” PMID 19331437 ↗ 2009
Known as	Phenofibrate	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05909800 ↗
Known as	SYO-0805	“Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)” NCT01353404 ↗
Known as	Tricor	“Tricor® is the brand name for prescription fenofibrate pills.” NCT01048502 ↗ 3 “fenofibrate (Tricor formulation)” NCT01148004 ↗ “TRICOR (fenofibrate)” NCT02158273 ↗ NCT00251680 ↗
Known as	Trolip	“Eligible subjects will be prescribed the study drug, fenofibrate (Trolip®).” NCT03869931 ↗
Action	Activate	“PPAR-alpha agonist” NCT00252499 ↗
Modality	Small molecule	“Fenofibrate is a fibric acid postulated to regulate immune response and cell proliferation.” PMID 21083674 ↗ Nov 2010
Route	Oral	“micronized fenofibrate 200 mg 1 po qd” NCT00252499 ↗
Target	PPARA	“PPAR-alpha agonist” NCT00252499 ↗